Dr. Riad Salem, Yttrium-90 radioembolization expert, to narrate liver cancer treatment in Chicago
June 14, 2012
/PRNewswire/ - Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, today announced that organizers of the World Congress on Interventional Oncology (WCIO) 2012 will be hosting a live administration of Nordion's TheraSphere
Yttrium-90 (Y-90) glass microsphere liver cancer treatment
The administration will take place on
Thursday, June 14
5 PM CST
in the context of an approved Continuing Medical Education program organized by WCIO. The treatment will be administered to a pre-screened patient at Northwestern Memorial Hospital (
and broadcast live via video link to physicians attending WCIO, which takes place in
. Real-time narration of the procedure will be provided by
, MD, Professor of Radiology, Medicine and Surgery and Director, Interventional Oncology at
, and one of the world's foremost experts in
radioembolization for liver cancer.
"We are pleased with WCIO's initiative to present a live case demonstration of TheraSphere®," said
, MD, Nordion's Vice President of Medical Affairs. "This promises to be a valuable and unique learning opportunity for physicians considering the use of TheraSphere®. Observers will be able to see first-hand how generally well-tolerated and fast the infusion is as a liver-directed therapy."
Nordion representatives attending WCIO will be at
to meet with physicians and journalists. Among other topics, Nordion will be providing more information on the new TheraSphere
custom dose feature, which was
launched last month in Canada and the EU
and is now available in the US. In addition, Nordion will be demonstrating the new
App for iPad
, created for healthcare providers and now available for download through the Apple App Store and iTunes. Nordion is also providing
to the WCIO Fellows' Scholarship Fund, which provides interventional radiology fellows training in the latest interventional oncology techniques, therapies, and research presented by multidisciplinary international faculty.
is a liver cancer therapy that consists of millions of small glass beads (20 to 30 micrometers in diameter) containing radioactive
. The product is injected by physicians into the artery of the patient's liver through a catheter, which allows the treatment to be delivered directly to the tumour via blood flow.
In the US, TheraSphere
is used to treat patients with HCC who can have appropriately positioned hepatic arterial catheters, and can be used as a bridge to surgery or transplantation in these patients. It is also indicated for the treatment of HCC patients with partial or branch portal vein thrombosis or occlusion when clinical evaluation warrants the treatment. TheraSphere
is approved by the U.S. Food and Drug Administration (FDA) under a Humanitarian Device Exemption (HDE). HDE approvals are based on demonstrated safety and probable clinical benefit. However, effectiveness of the indication for use has not been established.
Common side effects include mild to moderate fatigue, pain and nausea for about a week. Physicians describe these symptoms as similar to those of the flu. Some patients experience some loss of appetite and temporary changes in several blood tests. For details on rare or more severe side effects, please refer to the TheraSphere
package insert/instructions for use at
About Nordion Inc.
Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global health science company that provides market-leading products used for the prevention, diagnosis and treatment of disease. We are a leading provider of
that benefit the lives of millions of people in more than 60 countries around the world. Our products are used daily by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics and research laboratories. Nordion has more than 500 highly skilled employees in three locations. Find out more at
and follow us at
SOURCE Nordion Inc.